Core Insights - OSE Immunotherapeutics has appointed Thomas Gidoin as Chief Financial Officer, bringing over 15 years of international expertise in capital markets and financial strategy [1][5][6] - Gidoin has a strong background in biopharma finance, having previously served as CFO at Advesya and GenSight Biologics, where he led financing strategies from Series B to IPO [2][3] - The company is positioned for growth with two late-stage assets in oncology and inflammation, supported by an innovative research platform [6][7] Company Overview - OSE Immunotherapeutics is focused on developing first-in-class assets in immuno-oncology and immuno-inflammation to address unmet patient needs [7] - The company collaborates with leading academic institutions and biopharmaceutical companies to bring transformative medicines to market [7] - OSE Immunotherapeutics is based in Nantes and Paris and is listed on Euronext [7]